Chromatin remodeling factor LSH is upregulated by the LRP6-GSK3β-E2F1 axis linking reversely with survival in gliomas

Theranostics

Volumn 7, Issue 1, 2017, Pages 132-143

  Xiao, Desheng ^a,b   Huang, Jun ^a   Pan, Yu ^a,b   Li, Hao ^a   Fu, Chunyan ^a,b   Mao, Chao ^b,c   Cheng, Yan ^b   Shi, Ying ^b,c   Chen, Ling ^b,c   Jiang, Yiqun ^b,c   Yang, Rui ^b,c   Liu, Yating ^b,c   Zhou, Jianhua ^a,b   Cao, Ya ^b,c   Liu, Shuang ^a   Tao, Yongguang ^a,b,c  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

Astrocytomas; E2F1; Gioblastoma; GSK3 ; LRP6; LSH

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3BETA; HELICASE; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 6; LYMPHOID SPECIFIC HELICASE; TRANSCRIPTION FACTOR E2F1; UNCLASSIFIED DRUG; DNA HELICASE; E2F1 PROTEIN, HUMAN; GSK3B PROTEIN, HUMAN; HELLS PROTEIN, HUMAN; LRP6 PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASTROCYTOMA; CANCER GRADING; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; CELL GROWTH; CHILD; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; CORRELATION ANALYSIS; ECTOPIC EXPRESSION; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; GENE SILENCING; GLIOBLASTOMA; GLIOMA; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROMOTER REGION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN TRANSPORT; SCHOOL CHILD; SIGNAL TRANSDUCTION; UPREGULATION; GENE EXPRESSION REGULATION; METABOLISM; PATHOPHYSIOLOGY; SURVIVAL;

ASTROCYTOMA; CHROMATIN ASSEMBLY AND DISASSEMBLY; DNA HELICASES; E2F1 TRANSCRIPTION FACTOR; GENE EXPRESSION REGULATION; GLYCOGEN SYNTHASE KINASE 3 BETA; HUMANS; LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN-6; SURVIVAL;

EID: 84999750706     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.17032     Document Type: Article

References (55)

1. Van Meir EG, Hadjipanayis CG, Norden AD, et al. Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin 2010; 60: 166-193.
2. Cloughesy TF, Cavenee WK, Mischel PS. Glioblastoma: from molecular pathology to targeted treatment. Annu Rev Pathol 2014; 9: 1-25.
3. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10: 459-466.
4. Messaoudi K, Clavreul A, Lagarce F. Toward an effective strategy in glioblastoma treatment. Part I: resistance mechanisms and strategies to overcome resistance of glioblastoma to temozolomide. Drug Discov Today 2015; 20: 899-905.
5. Sehedic D, Cikankowitz A, Hindre F, et al. Nanomedicine to overcome radioresistance in glioblastoma stem-like cells and surviving clones. Trends Pharmacol Sci 2015; 36: 236-252.
6. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996.
7. Mazor T, Pankov A, Johnson BE, et al. DNA Methylation and Somatic Mutations Converge on the Cell Cycle and Define Similar Evolutionary Histories in Brain Tumors. Cancer Cell 2015; 28: 307-317.
8. Ceccarelli M, Barthel FP, Malta TM, et al. Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. Cell 2016; 164: 550-563.
9. Erdem-Eraslan L, Gravendeel LA, de Rooi J, et al. Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. J Clin Oncol 2013; 31: 328-336.
10. Cancer Genome Atlas Research N, Brat DJ, Verhaak RG, et al. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med 2015; 372: 2481-2498.
11. Eckel-Passow JE, Lachance DH, Molinaro AM, et al. Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. N Engl J Med 2015; 372: 2499-2508.
12. Wilson BG, Roberts CW. SWI/SNF nucleosome remodellers and cancer. Nat Rev Cancer 2011; 11: 481-492.
13. Zemach A, Kim MY, Hsieh PH, et al. The Arabidopsis nucleosome remodeler DDM1 allows DNA methyltransferases to access H1-containing heterochromatin. Cell 2013; 153: 193-205.
14. Yu W, McIntosh C, Lister R, et al. Genome-wide DNA methylation patterns in LSH mutant reveals de-repression of repeat elements and redundant epigenetic silencing pathways. Genome Res 2014; 24: 1613-1623.
15. Tao Y, Xi S, Shan J, et al. Lsh, chromatin remodeling family member, modulates genome-wide cytosine methylation patterns at nonrepeat sequences. Proc Natl Acad Sci U S A 2011; 108: 5626-5631.
16. Myant K, Termanis A, Sundaram AY, et al. LSH and G9a/GLP complex are required for developmentally programmed DNA methylation. Genome Res 2011; 21: 83-94.
17. Fan T, Yan Q, Huang J, et al. Lsh-deficient murine embryonal fibroblasts show reduced proliferation with signs of abnormal mitosis. Cancer Res 2003; 63: 4677-4683.
18. Burrage J, Termanis A, Geissner A, et al. The SNF2 family ATPase LSH promotes phosphorylation of H2AX and efficient repair of DNA double-strand breaks in mammalian cells. J Cell Sci 2012; 125: 5524-5534.
19. Keyes WM, Pecoraro M, Aranda V, et al. DeltaNp63alpha is an oncogene that targets chromatin remodeler Lsh to drive skin stem cell proliferation and tumorigenesis. Cell Stem Cell 2011; 8: 164-176.
20. von Eyss B, Maaskola J, Memczak S, et al. The SNF2-like helicase HELLS mediates E2F3-dependent transcription and cellular transformation. EMBO J 2012; 31: 972-985.
21. Yu W, Briones V, Lister R, et al. CG hypomethylation in Lsh-/-mouse embryonic fibroblasts is associated with de novo H3K4me1 formation and altered cellular plasticity. Proc Natl Acad Sci U S A 2014; 111: 5890-5895.
22. Ryu B, Kim DS, Deluca AM, et al. Comprehensive expression profiling of tumor cell lines identifies molecular signatures of melanoma progression. PLoS One 2007; 2: e594.
23. He X, Yan B, Liu S, et al. Chromatin remodeling factor LSH drives cancer progression by suppressing the activity of fumarate hydratase. Cancer Res 2016.
24. Cohen P, Frame S. The renaissance of GSK3. Nat Rev Mol Cell Biol 2001; 2: 769-776.
25. Atkins RJ, Stylli SS, Luwor RB, et al. Glycogen synthase kinase-3beta (GSK-3beta) and its dysregulation in glioblastoma multiforme. J Clin Neurosci 2013; 20: 1185-1192.
26. Tang QL, Xie XB, Wang J, et al. Glycogen synthase kinase-3beta, NF-kappaB signaling, and tumorigenesis of human osteosarcoma. J Natl Cancer Inst 2012; 104: 749-763.
27. Dajani R, Fraser E, Roe SM, et al. Crystal structure of glycogen synthase kinase 3 beta: structural basis for phosphate-primed substrate specificity and autoinhibition. Cell 2001; 105: 721-732.
28. Garcia-Alvarez G, Ventura V, Ros O, et al. Glycogen synthase kinase-3beta binds to E2F1 and regulates its transcriptional activity. Biochim Biophys Acta 2007; 1773: 375-382.
29. Morris EJ, Ji JY, Yang F, et al. E2F1 represses beta-catenin transcription and is antagonized by both pRB and CDK8. Nature 2008; 455: 552-556.
30. Bell LA, Ryan KM. Life and death decisions by E2F-1. Cell Death Differ 2004; 11: 137-142.
31. Polager S, Ginsberg D. p53 and E2f: partners in life and death. Nat Rev Cancer 2009; 9: 738-748.
32. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006; 127: 469-480.
33. Stamos JL, Chu ML, Enos MD, et al. Structural basis of GSK-3 inhibition by N-terminal phosphorylation and by the Wnt receptor LRP6. Elife 2014; 3: e01998.
34. Cheng PW, Chen YY, Cheng WH, et al. Wnt Signaling Regulates Blood Pressure by Downregulating a GSK-3beta-Mediated Pathway to Enhance Insulin Signaling in the Central Nervous System. Diabetes 2015; 64: 3413-3424.
35. MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell 2009; 17: 9-26.
36. Chen S, Bubeck D, MacDonald BT, et al. Structural and functional studies of LRP6 ectodomain reveal a platform for Wnt signaling. Dev Cell 2011; 21: 848-861.
37. Anastas JN, Moon RT. WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer 2013; 13: 11-26.
38. Jiang Y, Yan B, Lai W, et al. Repression of Hox genes by LMP1 in nasopharyngeal carcinoma and modulation of glycolytic pathway genes by HoxC8. Oncogene 2015; 34: 6079-6091.
39. Shi Y, Tao Y, Jiang Y, et al. Nuclear epidermal growth factor receptor interacts with transcriptional intermediary factor 2 to activate cyclin D1 gene expression triggered by the oncoprotein latent membrane protein 1. Carcinogenesis 2012; 33: 1468-1478.
40. Voskas D, Ling LS, Woodgett JR. Does GSK-3 provide a shortcut for PI3K activation of Wnt signalling? F1000 Biol Rep 2010; 2: 82.
41. Ren J, Briones V, Barbour S, et al. The ATP binding site of the chromatin remodeling homolog Lsh is required for nucleosome density and de novo DNA methylation at repeat sequences. Nucleic Acids Res 2015; 43: 1444-1455.
42. Huang J, Fan T, Yan Q, et al. Lsh, an epigenetic guardian of repetitive elements. Nucleic Acids Res 2004; 32: 5019-5028.
43. Yan Q, Cho E, Lockett S, et al. Association of Lsh, a regulator of DNA methylation, with pericentromeric heterochromatin is dependent on intact heterochromatin. Mol Cell Biol 2003; 23: 8416-8428.
44. Jiang Y, Liu S, Chen X, et al. Genome-wide distribution of DNA methylation and DNA demethylation and related chromatin regulators in cancer. Biochim Biophys Acta 2013; 1835: 155-163.
45. Liu S, Tao Y. Interplay between chromatin modifications and paused RNA polymerase II in dynamic transition between stalled and activated genes. Biol Rev Camb Philos Soc 2013; 88: 40-48.
46. Delatte B, Deplus R, Fuks F. Playing TETris with DNA modifications. EMBO J 2014; 33: 1198-1211.
47. Shen L, Zhang Y. 5-Hydroxymethylcytosine: generation, fate, and genomic distribution. Curr Opin Cell Biol 2013; 25: 289-296.
48. Turcan S, Rohle D, Goenka A, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 2012; 483: 479-483.
49. Xu W, Yang H, Liu Y, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell 2011; 19: 17-30.
50. Ficz G, Gribben JG. Loss of 5-hydroxymethylcytosine in cancer: cause or consequence? Genomics 2014; 104: 352-357.
51. Muller T, Gessi M, Waha A, et al. Nuclear exclusion of TET1 is associated with loss of 5-hydroxymethylcytosine in IDH1 wild-type gliomas. Am J Pathol 2012; 181: 675-683.
52. Murata A, Baba Y, Ishimoto T, et al. TET family proteins and 5-hydroxymethylcytosine in esophageal squamous cell carcinoma. Oncotarget 2015.
53. Hara K, Kageji T, Mizobuchi Y, et al. Blocking of the interaction between Wnt proteins and their co-receptors contributes to the anti-tumor effects of adenovirus-mediated DKK3 in glioblastoma. Cancer Lett 2015; 356: 496-505.
54. Zhang W, Shen C, Li C, et al. miR-577 inhibits glioblastoma tumor growth via the Wnt signaling pathway. Mol Carcinog 2015.
55. Pyko IV, Nakada M, Sabit H, et al. Glycogen synthase kinase 3beta inhibition sensitizes human glioblastoma cells to temozolomide by affecting O6-methylguanine DNA methyltransferase promoter methylation via c-Myc signaling. Carcinogenesis 2013; 34: 2206-2217.